Titel

Merkliste
1 Ergebnisse

A phase 2, multicenter, open-label study of anti-LAG-3 iera..:

Chia-Chi Lin ; Elena Garralda ; Patrick Schöffski...
https://www.tandfonline.com/doi/10.1080/2162402X.2023.2290787. , 2024

Link: https://doi.org/10.1080/2162402X.2023.2290787

RT Journal
T1 <Title>A phase 2, multicenter, open-label study of anti-LAG-3 ieramilimab in combination with anti-PD-1 spartalizumab in patients with advanced solid malignancies</Title>

UL https://suche.suub.uni-bremen.de/peid=base-ftdoajarticles:oai:doaj.org_article:fba32163599d40e7abcb0008f2589a1a&Exemplar=1&LAN=DE
				
A1 Chia-Chi Lin
A1 Elena Garralda
A1 Patrick Schöffski
A1 David S. Hong
A1 Lillian L. Siu
A1 Miguel Martin
A1 Michela Maur
A1 Rina Hui
A1 Ross A Soo
A1 Joanne Chiu
A1 Tian Zhang
A1 Brigette Ma
A1 Chrisann Kyi
A1 Daniel SW Tan
A1 Philippe A. Cassier
A1 John Sarantopoulos
A1 Andrew Weickhardt
A1 Richard D. Carvajal
A1 Jennifer Spratlin
A1 Taito Esaki
A1 Fréderic Rolland
A1 Wallace Akerley
A1 Barbara Deschler-Baier
A1 Lawrence Rispoli
A1 Tanay S. Samant
A1 Niladri Roy Chowdhury
A1 Daniel Gusenleitner
A1 Eunice L. Kwak
A1 Vasileios Askoxylakis
A1 Filippo De Braud
PB Taylor & Francis Group
YR 2024
K1 Efficacy
K1 ieramilimab
K1 LAG-3 inhibitor
K1 safety
K1 spartalizumab
K1 Immunologic diseases. Allergy
K1 RC581-607
K1 Neoplasms. Tumors. Oncology. Including cancer and carcinogens
K1 RC254-282
JF https://www.tandfonline.com/doi/10.1080/2162402X.2023.2290787
LK http://dx.doi.org/https://doi.org/10.1080/2162402X.2023.2290787
DO https://doi.org/10.1080/2162402X.2023.2290787
SF ELIB - SuUB Bremen

Export

RefWorks (nur Desktop-Version!)
Flow (Zuerst in Flow einloggen, dann importieren)